BCL2 and cancer: Agents that specifically target apoptotic machinery including tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptors, the BCL2 family of anti-apoptotic proteins, inhibitor of apoptosis (IAP) and MDM2 are currently being explored for cancer drug discovery [10].